| Name | Bradykinin |
| Description | Bradykinin is an inflammatory mediator. It is a peptide that causes blood vessels to dilate (enlarge) via the release of prostacyclin, nitric oxide, and Endothelium-Derived Hyperpolarizing Factor. Bradykinin is a physiologically and pharmacologically active peptide of the kinin group of proteins, consisting of nine amino acids. |
| In vitro | Bradykinin is a potent vasodilator peptide that exerts its vasodilatory action through stimulation of specific endothelial B2 receptors, thereby causing the release of prostacyclin, NO, and EDHF[1]. Bradykinin has been reported to be involved in the progression of many types of cancer. Bradykinin treatment stimulates ERK1/2 activation and IL-6 production thereby contributing to the invasion and migration of colorectal cancer cells. [2]. Exogenous bradykinin markedly inhibits TF expression in mRNA and protein level induced by LPS in a dose-dependent manner. The NO synthase antagonist L-NAME and PI3K inhibitor LY294002 dramatically abolish the inhibitory effects of bradykinin on tissue factor expression[3]. |
| In vivo | Application of 1 μM bradykinin to the ovary produces significant decreases in heart rate and mean arterial pressure. Application of 1 μM bradykinin to the ovary produces bradycardia and hypotension similar to the responses evoked when vagal innervation is intact in vagotomized animals[4]. Vascular bradykinin can improve pancreatic microcirculation and hemorheology in rats with severe acute pancreatitis. The pancreatic microcirculatory blood flow volume and velocity in the vascular bradykinin treatment group increases gradually after 48 h[5]. PI3K/Akt signaling pathway activation induced by bradykinin administration reduces the activity of GSK-3β and MAPK, and reduces NF-x03BA;B level in the nucleus, thereby inhibiting TF expression. Consistent with this, intraperitoneal injection of C57/BL6 mice with bradykinin also inhibits the thrombus formation induced by ligation of inferior vena cava[3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 10 mM, Sonication is recommended.
H2O : 100 mg/mL (94.32 mM), Sonication is recommended.
|
| Keywords | Threonine proteases | Serine proteases | Serine endopeptidases | Ser/Thr Protease | Inhibitor | inhibit | EndogenousMetabolite | Endogenous Metabolite | BradykininReceptor | Bradykinin Receptor | Bradykinin |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | DL-Lysine | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Imidazole | Malic acid | Glycerol | Thymidine | Corn starch | Gluconate Calcium |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Natural Product Library | Natural Product Library for HTS | Human Endogenous Metabolite Library | Immunology/Inflammation Compound Library | Human Endogenous Metabolite Compound Library Plus | Bioactive Compounds Library Max | GPCR Compound Library |
United States
